Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417593 | 0.90 | CYP11B2 (0.33) | KDM4EL3MBTL1CYP11B2GAA | |
| SCHEMBL25346855 | 0.84 | — | — | |
| SCHEMBL22501957 | 0.78 | — | — | |
| SCHEMBL3733449 | 0.76 | KDM4E (0.33) | KDM4EL3MBTL1 | |
| SCHEMBL136340 | 0.73 | — | — | |
| SCHEMBL428515 | 0.73 | — | — | |
| SCHEMBL16969390 | 0.72 | GAA (0.34) | ESR2KDM4EL3MBTL1GAA | |
| SCHEMBL1802879 | 0.72 | GAA (0.33) | KDM4EL3MBTL1GAA | |
| SCHEMBL4688167 | 0.72 | LMNA (0.48) | KDM4EL3MBTL1 | |
| SCHEMBL16877327 | 0.71 | TTR (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735439-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4720067-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | Recursion Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| US-20250179065-A1 | HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| CN-118420559-B | Deuterated oxadiazinone compound and application thereof | 上海超阳药业有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| WO-2025006967-A1 | KRAS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-02 | — | — | WO | disclosed |
| WO-2024246559-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | EXSCIENTIA AI LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| EP-4464703-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-01-21 | — | — | US | disclosed |
| EP-2558468-B1 | 5, 7-SUBSTITUTED-IMIDAZO [1,2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8962596-B2 | 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases | ARRAY BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2558468-A1 | 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | Array Biopharma, Inc. (US) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011130146-A1 | 5, 7-SUBSTITUTED-IMIDAZO [1, 2-C] PYRIMIDINES AS INHIBITORS OF JAK KINASES | ARRAY BIOPHARMA INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| US-7439263-B2 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2008-10-21 | — | — | US | disclosed |
| EP-1598350-B1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | SERVIER LAB (FR) | 2007-07-11 | — | — | EP | disclosed |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | LES LABORATOIRES SERVIER (FR) | 2005-11-24 | — | — | US | disclosed |
| EP-1598350-A1 | Pyrrolidines and thiazolidines derivatives, their preparation and their use in the treatment of hyperglycaemia and of type II Diabetis | LES LABORATOIRES SERVIER (FR) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | IKZF2, IKZF1, IKZF3 | ESR2 1037/4885KDM4E 233/4885L3MBTL1 909/4885 |
| US-20130131039-A1 | 5,7-SUBSTITUTED-IMIDAZO[1,2-C]PYRIMIDINES AS INHIBITORS OF JAK KINASES | JAK1, JAK3, JAK2 | ESR2 2919/4885KDM4E 1383/4885L3MBTL1 822/4885 |
| US-20050261501-A1 | Pyrrolidine and thiazolidine compounds | DPP4, DPP3, NR4A1 | ESR2 370/4885KDM4E 812/4885L3MBTL1 3009/4885 |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | ESR2 130/4885KDM4E 4023/4885L3MBTL1 1536/4885 |
| US-20250179065-A1 | HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | ESR2 3607/4885KDM4E 2431/4885L3MBTL1 2238/4885 |
| US-20210017177-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | ESR2 130/4885KDM4E 4023/4885L3MBTL1 1536/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | ESR2 130/4885KDM4E 4023/4885L3MBTL1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.